Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
CAL-85-1 Topotecan
0.031667
Topo I
Chemotherapy
 0.1839 0.17720
CAL-85-1 Topotecan
0.1
Topo I
Chemotherapy
 -0.0710 0.31688
CAL-85-1 Topotecan
0.31623
Topo I
Chemotherapy
 -0.1749 0.44801
CAL-85-1 Topotecan
1.0
Topo I
Chemotherapy
 -0.2450 0.46665
CAL-85-1 Topotecan
3.1623
Topo I
Chemotherapy
 -0.2957 0.48230
CAL-85-1 Topotecan
10.0
Topo I
Chemotherapy
 -0.2909 0.48550
CAL-85-1 Etoposide
0.0010833
Topo II
Chemotherapy
 1.0069 -0.00155
CAL-85-1 Etoposide
0.0033333
Topo II
Chemotherapy
 0.9619 0.00647
CAL-85-1 Etoposide
0.01
Topo II
Chemotherapy
 1.0147 0.00389
CAL-85-1 Etoposide
0.031667
Topo II
Chemotherapy
 0.9844 0.00551
CAL-85-1 Etoposide
0.1
Topo II
Chemotherapy
 0.8558 0.02838
CAL-85-1 Etoposide
0.31623
Topo II
Chemotherapy
 0.6308 0.04927
CAL-85-1 Etoposide
1.0
Topo II
Chemotherapy
 0.1239 0.23957
CAL-85-1 Etoposide
3.1623
Topo II
Chemotherapy
 -0.1793 0.36518
CAL-85-1 Etoposide
10.0
Topo II
Chemotherapy
 -0.2411 0.39938
CAL-85-1 Dasatinib
0.001
BCR/ABL
MAPK/nRTK
 0.9611 0.01416
CAL-85-1 Dasatinib
0.0031623
BCR/ABL
MAPK/nRTK
 0.9527 0.01160
CAL-85-1 Dasatinib
0.01
BCR/ABL
MAPK/nRTK
 1.0427 0.02391
CAL-85-1 Dasatinib
0.031623
BCR/ABL
MAPK/nRTK
 1.0278 0.04976
CAL-85-1 Dasatinib
0.1
BCR/ABL
MAPK/nRTK
 0.4751 0.18204
CAL-85-1 Dasatinib
0.31623
BCR/ABL
MAPK/nRTK
 0.0080 0.29960
CAL-85-1 Dasatinib
1.0
BCR/ABL
MAPK/nRTK
 -0.1864 0.38590
CAL-85-1 Dasatinib
3.1623
BCR/ABL
MAPK/nRTK
 -0.2438 0.48822
CAL-85-1 Dasatinib
10.0
BCR/ABL
MAPK/nRTK
 -0.2405 0.48315
CAL-85-1 Trametinib
0.0001
MEK
MAPK/nRTK
 1.0115 0.00803